Company Announcements

Director Declaration

Source: RNS
RNS Number : 1214V
Reckitt Benckiser Group PLC
05 August 2022
 

 

05 August 2022

 

 

RECKITT BENCKISER GROUP PLC

 

Director Declaration

 

Reckitt Benckiser Group plc ("Reckitt") announces that Alan Stewart, non-executive director, has been appointed as a non-executive director of Burberry Group plc, and as a member of the Audit and Nomination committees of Burberry Group plc, with effect from 1 September 2022.

 

This notification is made in accordance with Listing Rule 9.6.14 of the FCA's Listing Rules.

 

 

For further Information: 

 

Catheryn O'Rourke

Company Secretary

Tel +44 (0) 1753 217 800

 

Richard Joyce

Investor Relations Director

Tel. +44 (0) 7408 812 062

 

 

About Reckitt: 

 

Reckitt* exists to protect, heal and nurture in the relentless pursuit of a cleaner, healthier world. We believe that access to the highest-quality hygiene, wellness and nourishment is a right, not a privilege. 

 

Reckitt is the company behind some of the world's most recognisable and trusted consumer brands in hygiene, health and nutrition, including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, Woolite and more. 

 

Every day, more than 20 million Reckitt products are bought globally. We always put consumers and people first, seek out new opportunities, strive for excellence in all that we do and build shared success with all our partners. We aim to do the right thing, always. 

 

We are a diverse global team of more than 43,000 colleagues. We draw on our collective energy to meet our ambitions of purpose-led brands, a healthier planet and a fairer society. Find out more, or get in touch with us at www.reckitt.com. 

 

*Reckitt is the trading name of the Reckitt Benckiser group of companies 

 

 

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNPAMMTMTAMBFT